Protein kinase inhibitors
    1.
    发明授权
    Protein kinase inhibitors 失效
    蛋白激酶抑制剂

    公开(公告)号:US06346625B1

    公开(公告)日:2002-02-12

    申请号:US09403720

    申请日:1999-10-25

    IPC分类号: C07D40304

    摘要: The present invention relates to compounds of formula (I) wherein: Ar1 or Ar2 is an optionally substituted indole, and the other group is an optionally substituted aromatic or heteroaromatic group, preferably an optionally substituted indole, X is O or S, and R2 is H, hydroxy, amino, C1-6alkyl, hydroxyC1-6alkyl or aminoC1-6alkyl, and salts and solvates thereof and solvates of such salts, and the use of such compounds in medical therapies.

    摘要翻译: 本发明涉及式(I)化合物,其中:Ar 1或Ar 2是任选取代的吲哚,另一个基团是任选取代的芳族或杂芳族基团,优选任选取代的吲哚,X是O或S,R 2是H ,羟基,氨基,C 1-6烷基,羟基C 1-6烷基或氨基C 1-6烷基,及其盐和溶剂化物以及这些盐的溶剂合物,以及这些化合物在医学疗法中的用途。

    Pharmaceutically active compounds
    2.
    发明授权
    Pharmaceutically active compounds 失效
    药物活性化合物

    公开(公告)号:US06492406B1

    公开(公告)日:2002-12-10

    申请号:US09646972

    申请日:2000-09-25

    IPC分类号: C07D40314

    摘要: The present invention relates to novel compounds which are protein kinase C inhibitors, methods for their preparation, intermediates therefor and pharmaceutical compositions comprising them. More particularly, the present invention relates to compounds of formula (I): wherein: one of Ar1 and Ar2 is optionally substituted bicyclic heteroaryl or optionally substituted tricyclic heteroaryl and the other is optionally substituted heteroaryl or optionally substituted aryl; X is O or S; and R is H, OH, NH2 or C1-6 alkyl (itself optionally substituted by amino or hydroxy); or a salt or solvate thereof, or a solvate of a salt thereof; and the use of such compounds in medical therapies.

    摘要翻译: 本发明涉及蛋白激酶C抑制剂的新化合物,其制备方法,其中间体和包含它们的药物组合物。 更具体地说,本发明涉及式(I)的化合物:其中:Ar 1和Ar 2之一是任选取代的双环杂芳基或任选取代的三环杂芳基,另一个是任选取代的杂芳基或任选取代的芳基; X是O或S; 且R为H,OH,NH 2或C 1-6烷基(其本身任选被氨基或羟基取代); 或其盐或溶剂合物,或其盐的溶剂合物; 以及这些化合物在医学疗法中的应用。

    Kinase inhibitors
    3.
    发明授权
    Kinase inhibitors 失效
    激酶抑制剂

    公开(公告)号:US06492409B1

    公开(公告)日:2002-12-10

    申请号:US09743618

    申请日:2001-01-12

    IPC分类号: A61K314178

    摘要: The present invention relates to compounds of formula (I) wherein: Ar1 or Ar2 is an optionally substituted indole, and the other group is an optionally substituted aromatic or heteroaromatic group, suitably an optionally substituted bicyclic heteroaromatic group, preferably an optionally substituted indole, X is O or S, R is H, OH, NH2, C1-6alkyl, hydroxyC1-6alkyl, aminoC1-6alkyl, and R1 is H, C1-6alkyl, fluoro substituted C1-6alkyl, phenyl, benzyl, carboC1-6alkoxy, carbobensyloxy, carbohydroxy, carbamoyl, or methyl(N-C1-6alkylcarbamoyl) and salts and solvates thereof and solvates of such salts, and the use of such compounds in medical therapies.

    摘要翻译: 本发明涉及式(I)化合物,其中:Ar 1或Ar 2是任选取代的吲哚,另一个基团是任选取代的芳族或杂芳族基团,合适地是任选取代的双环杂芳族基团,优选任选取代的吲哚,X 是O或S,R是H,OH,NH 2,C 1-6烷基,羟基C 1-6烷基,氨基C 1-6烷基,R 1是H,C 1-6烷基,氟取代的C 1-6烷基,苯基,苄基,碳C 1-6烷氧基,碳苯氧基, ,氨基甲酰基或甲基(N-C 1-6烷基氨基甲酰基)及其盐和溶剂合物以及这些盐的溶剂合物,以及这些化合物在医学疗法中的用途。

    Bis-aryl or heteroaryl indoles
    4.
    发明授权
    Bis-aryl or heteroaryl indoles 失效
    双芳基或杂芳基吲哚

    公开(公告)号:US06337342B1

    公开(公告)日:2002-01-08

    申请号:US09230710

    申请日:1999-01-29

    IPC分类号: A61K314152

    摘要: The present invention relates to compounds of formula (I): wherein: Ar is an optionally substituted aromatic or heteroaromatic group, R1 is H, C1-6alkyl, CF3, phenyl, benzyl, carboC1-6alkoxy, carbamoyl, or methyl(N—C1-6alkylcarbamoyl) R2 is H, C1-6alkyl, aminoC1-6alkyl, hydroxyC1-6alkyl, (mono- or di- C1-6alkyl)aminoC1-6alkyl, (aminoC1-3alkylphenyl)C1-3alkyl, amidinothio C1-6alkyl, R3 is H or C1-6alkoxy, R4 is H or together with R2, forms an annulated ring which may be substituted by hydroxyC1-3alkyl or amidinothio C1-3alkyl, or aminoC1-3alkyl; and pharmaceutically acceptable salts thereof; and the use of such compounds in medical therapies.

    摘要翻译: 本发明涉及式(I)的化合物:其中:Ar是任选取代的芳族或杂芳族基团,R 1是H,C 1-6烷基,CF 3,苯基,苄基,C 1 -C 6烷氧基,氨基甲酰基或甲基(N-C 1 (烷基氨基甲酰基)R 2是H,C 1-6烷基,氨基C 1-6烷基,羟基C 1-6烷基,(单 - 或二 - C 1-6烷基)氨基C 1-6烷基,(氨基C 1-3烷基苯基)C 1-3烷基,脒基硫代C 1-6烷基,R 3是H 或C 1-6烷氧基,R 4是H或与R 2一起形成可以被羟基C 1-3烷基或脒基C 1-3烷基或氨基C 1-3烷基取代的环状环;及其药学上可接受的盐;以及这些化合物在医学上的用途 疗法。

    Compounds
    5.
    发明授权
    Compounds 失效
    化合物

    公开(公告)号:US06458792B1

    公开(公告)日:2002-10-01

    申请号:US09297543

    申请日:1999-05-03

    IPC分类号: A61K31498

    摘要: The present invention provides inhibitors of protein kinase C, of formula (I) wherein: one of: R1 and R2, R2 and R3 or R3 and R4, together form a 5 or 6 membered ring and the two groups of R1, R2, R3 and R4 not forming a ring, are H; and salts thereof, formulations comprising said inhibitors of protein kinase C of formula (I), processes for preparation thereof and use thereof in the manufacture of a medicament for the treatment of inflammatory, immunological, bronchopulmonary, cardiovascular, oncological or CNS-degenerative disorders.

    摘要翻译: 本发明提供式(I)的蛋白激酶C的抑制剂,其中:R1和R2之一,R2和R3或R3和R4一起形成5或6元环,R1,R2,R3两个基团 和R4不形成环的化合物是H;及其盐,包含式(I)的蛋白激酶C的所述抑制剂的制剂,其制备方法及其在制备用于治疗炎性,免疫性,支气管肺炎的药物中的用途 ,心血管,肿瘤或CNS退行性疾病。

    Pharmaceutically active compounds
    6.
    发明授权
    Pharmaceutically active compounds 失效
    药物活性化合物

    公开(公告)号:US06271231B1

    公开(公告)日:2001-08-07

    申请号:US08981266

    申请日:1997-12-18

    IPC分类号: A61K31498

    摘要: The present invention provides optionally substituted and/or annulated compounds of formula (I) wherein X, Y, Z and A is each independently carbon or nitrogen, and at least two of X, Y, Z and A are carbon; and pharmaceutically acceptable salts thereof with the proviso that: 3-(1H-Indol-3-yl)-1H-quinoxalin-2-one, 3-(2-Methyl-1H-indol-3-yl)-1H-quinoxalin-2-one, and 3-(1,2-Diphenyl-1H-indol-3-yl)-1H-quinoxalin-2-one are excluded from compounds of formula (I). The invention includes the use of compounds of formula (I) in medical therapy, particularly in the therapy of conditions requiring inhibition of protein kinase C.

    摘要翻译: 本发明提供任选取代的和/或赋形的式(I)化合物,其中X,Y,Z和A各自独立地为碳或氮,X,Y,Z和A中的至少两个为碳;和药学上可接受的盐 其条件是:3-(1H-吲哚-3-基)-1H-喹喔啉-2-酮,3-(2-甲基-1H-吲哚-3-基)-1H-喹喔啉-2-酮, 和3-(1,2-二苯基-1H-吲哚-3-基)-1H-喹喔啉-2-酮从式(I)化合物中排除。 本发明包括式(I)化合物在药物治疗中的用途,特别是在治疗需要抑制蛋白激酶C的病症中。